Table 3.
Five randomized controlled trials of interferon-α in the treatment of chronic hepatitis D
| Author | Case no. | HBeAg/HBV DNA(+) | Dose | CR-EOT | CR-EFU | ||
|---|---|---|---|---|---|---|---|
| Rx | Cont | Rx | Cont | ||||
| Rosina [39], Italy | 23 | 4 (17%) | 5 MU/m2 tiw ×3 M | 3/11 | 0/12 | NA | |
| Porres [40], Spain | 20 | 0 | 10 MU/m2 tiw ×6 M | NA | 2/10 at 15 M | 0/10 | |
| Rosina [41], Italy | 61 | 9 (15%) | 5 MU/m2 tiw ×4 M then 3 MU/m2 tiw ×8 M | 8/31 | 0/30 | 1/31 at 24 M | 0/30 |
| Farci [42], Italy | 42 | 2 (5%) | 9 MU tiw ×48 W, 3 MU tiw ×48 W | 9 MU 3 MU 7/14, 3/14 |
0/14 |
9 MU 3 MU 3/14, 0/14 |
0/14 |
| Di Marco [43], Italy (children) | 26 | 8 (31%) | 5 MU/m2 tiw ×4 M, then | MTG | LTG | MTG | LTG |
| 3 MU/m2 tiw ×8 M (MTG) | 5/13a | 7/13a | 0/13a | 2/13a | |||
| 3 MU/m2 tiw ×20 M (LTG) | 7/10b | NA | 2/10b | NA | |||
Note: CR, complete response; EOT, end of treatment; EFU, end of follow-up; Rx, treatment; Cont, control; MTG, medium term group; LTG, long-term group; NA, not available
aBiochemical response
bVirological response